Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Vir Biotechnology

NASDAQ: VIR ↗$11.70 USD
#Infectious Disease#Oncology#Immunology

Clinical-stage biotech developing antibody and siRNA therapeutics for infectious disease, with a growing oncology pipeline built on its PRO-XTEN masking platform.

Company Info

Sector:Biotechnology
Headquarters:San Francisco, CA, USA
Founded:2016
Website:www.vir.bio/

Clinical Development Pipeline

tobevibart + elebsiran

Target: HBsAg monoclonal antibody + HBV siRNA
Chronic hepatitis delta virus infection
Preclinical
Phase 1
Phase 2
Phase 3
Approved

tobevibart + elebsiran

Target: HBsAg monoclonal antibody + HBV siRNA
Chronic hepatitis B
Preclinical
Phase 1
Phase 2
Phase 3
Approved

VIR-5500

Target: PSMA (PRO-XTEN masked T-cell engager)
PSMA-positive metastatic castration-resistant prostate cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Marianne De Backer

President, Chief Executive Officer and Director (CEO since April 2023)

Jeff Calcagno

Executive Vice President and Chief Business Officer

Careers & Job Openings

See all open roles

All
San Francisco, CA
Apply Now →